IGC Pharma (NYSE: IGC) has announced promising preclinical results of its novel small molecule, IGC-M3, designed to address multiple biological drivers of Alzheimer’s disease.
According to IGC, IGC-M3 demonstrated activity in laboratory models against beta-amyloid aggregation, oxidative stress, mitochondrial dysfunction, and neuroinflammation, which are four key contributors to Alzheimer’s pathology.
Ram Mukunda, CEO of IGC, commented, “Few companies in the Alzheimer’s space are advancing both a late-stage cannabinoid-based therapy and an early-stage small molecule with multi-pathway potential. IGC-AD1 offers a near-term opportunity to address agitation, a debilitating symptom affecting up to 76% of Alzheimer’s patients using a combination of two actives one of which is low doses of THC, a naturally extracted cannabinoid, while IGC-M3 expands our reach further into disease modification. Together, they position IGC as a differentiated player in one of the largest unmet medical needs in the world.”
